(Q34791427)

4 August 2017

Safety and efficacy of tumor-targeted interleukin 12 gene therapy in treated and non-treated, metastatic lesions (English)

1 reference

4 August 2017

0 references

2

Glenn King

1 reference

4 August 2017

Jeffry Cutrera

1

1 reference

4 August 2017

Pamela Jones

3

1 reference

4 August 2017

Kristin Kicenuik

4

1 reference

4 August 2017

Elias Gumpel

5

1 reference

4 August 2017

Xueqing Xia

6

1 reference

4 August 2017

Shulin Li

7

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 January 2015

1 reference

4 August 2017

1 reference

4 August 2017

15

1 reference

4 August 2017

1

1 reference

4 August 2017

44-54

1 reference

Interleukin 12: still a promising candidate for tumor immunotherapy?

4 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4280356

Intricacies for posttranslational tumor-targeted cytokine gene therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4280356

Tumor Targeting via Integrin Ligands

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4280356

Immunocytokines: a review of molecules in clinical development for cancer therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4280356

The immunological profile of tumor-bearing animals determines the outcome of cancer immunotherapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4280356

Electrochemotherapy of cutaneous metastastes from breast cancer in elderly patients: a preliminary report

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4280356

IL-12 based gene therapy in veterinary medicine

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4280356

Plasmid IL-12 electroporation in melanoma.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4280356

A review of RGD-functionalized nonviral gene delivery vectors for cancer therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4280356

Vimentin in cancer and its potential as a molecular target for cancer therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4280356

Discovery of a linear peptide for improving tumor targeting of gene products and treatment of distal tumors by IL-12 gene therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4280356

Pre-clinical toxicity assessment of tumor-targeted interleukin-12 low-intensity electrogenetherapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4280356

Expression of WSX1 in tumors sensitizes IL-27 signaling-independent natural killer cell surveillance

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4280356

Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4280356

Interleukin-12: biological properties and clinical application

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4280356

Administration route- and immune cell activation-dependent tumor eradication by IL12 electrotransfer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4280356

Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4280356

Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4280356

Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4280356

An immunohistochemical study of the inflammatory infiltrate associated with nasal carcinoma in dogs and cats.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4280356

Intratumoral bleomycin and IL-12 electrochemogenetherapy for treating head and neck tumors in dogs.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4280356

Efficient electrotransfection into canine muscle

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4280356

Dose-finding in phase I clinical trials based on toxicity probability intervals.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4280356

Evaluation of toxicity following electrically mediated interleukin-12 gene delivery in a B16 mouse melanoma model

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4280356

Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4280356

Overexpression of vimentin in canine prostatic carcinoma

26 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25429465

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25429465

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2174/1566523214666141127093654

1 reference

4 August 2017

1 reference

4 August 2017

1 reference